Glenmark Launches Prasugrel In India
This article was originally published in PharmAsia News
Executive Summary
Glenmark announced that it will be the first in the Indian market to launch Prasugrel, the latest anti-platelet drug. The size of the anti-platelet market is close to $40 million and is dominated by clopidogrel. Glenmark will brand its drug as Aplet while the originator Daiichi Sankyo's brand is named as Effient